Compare Natera Inc. Common Stock (NTRA) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vertiv Holdings Co — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Vertiv Holdings Co trades at $216.16 (market cap $91.35B). The key difference: Vertiv Holdings Co is the larger of the two by market cap, and Vertiv Holdings Co pays a 0.11% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vertiv Holdings Co for 40 Days on average.
| NTRA | VRT | |
|---|---|---|
Market Cap | $57.03B | $91.35B |
Volume | 1,131,157 | 4,805,860 |
Sector | Health | Industrials |
52-Week High | $425.64 | $376.23 |
52-Week Low | $179.42 | $149.83 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $56.18B | $91.58B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Vertiv (VRT) trades at $237.29, down 0.86% on the day, amid a bearish technical signal. The stock exhibits strong fundamentals with revenue growth from $10.23B in 2025 to $11.5B projected for 2026 and a robust net income margin of 15.09%. Recent earnings have consistently beaten estimates, and analyst sentiment remains overwhelmingly positive with a 90.48% buy rating and a consensus price target of $366.12. However, technical indicators show selling pressure, with the price near support at $237.
The outlook for VRT is favorable due to its strategic position in the AI data center infrastructure market, driving revenue and margin expansion. Key risks include execution of growth initiatives, competitive pressures, and market volatility. The significant upside to the analyst target presents a potential opportunity, but investors should weigh the strong fundamentals against the current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
